Any medicine will receive its marketing authorisation only when the pharmaceutical company has demonstrated that the innovation is efficient, of high quality and safe for the users. In Europe, a large share of the pharmaceutical industry’s investments – about 30 billion euro – goes to medicine R&D.
Good research conditions
Pharma Industry Finland PIF has 15 years of statistics on the research done by the pharmaceutical industry in Finland. They show that Finland has a good and long reputation as an interesting country from the pharmaceutical research perspective.
For sometime we had seen some worrying trends in the number of research. However, now we have turned the trend and the investments of pharma companies are strongly increasing.
A key player for the change is the Finnish Health Sector Growth Strategy which was published in 2014. The strategy was formed in collaboration with ministry of economic affairs and employment, ministry of social welfare and health and with ministry of education and culture and with other stakeholders. Health sector growth strategy lists the key factors which will improve the research environment. With these factors we expect to get more investments in research and development in Finland.
I addition Finland will provide unique legislation in order to open our health and welfare registries to wider use. With the secondary use of health registries Finland provides an excellent environment for companies to use Finnish registries in research and development.
Investments in the coming two years
Number of Trials and Patients in Finland 2017
Trials by ATC Class 2017
Patients by ATC Class 2017
Registry Studies Change 2017
R&D Costs in Europe
R&D Costs in Europe, US and Japan
New Molecular Entities in Europe, US and Japan
R&D Share of Investments in Different Fields
Life Cycle of Product